Urinary Tract Infections of the Neurogenic Bladder

  • Mostafa RagabEmail author
  • Bob Yang
  • Melissa Davies
Part of the In Clinical Practice book series (ICP)


Patients with neurogenic lower urinary tract dysfunction (NLUTD) are at increased risk of recurrent urinary tract infection (UTI), with much higher incidence reported compared with a “normal” population. As a result, this leads to increased utilisation of healthcare resources as well as morbidity and even mortality in some cases. As expected, the underlying cause, as well as the investigation and management of UTIs in this unique population is different to patients with a “normal” bladder and will be explored further by this chapter.


  1. 1.
    Dorsher PT, McIntosh PM. Neurogenic bladder. Adv Urol. 2012;2012:816274. [published online February 8, 2012]CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Verhoef M, Lurvink M, Barf HA, et al. High prevalence of incontinence among young adults with spina bifida: description, prediction and problem perception. Spinal Cord. 2005;43:331–40.CrossRefGoogle Scholar
  3. 3.
    McNeal, D. M., Hawtrey, C. E., Wolraich, M. L. and Mapel, J. R. Symptomatic neurogenic bladder in a cerebral-palsied population. Dev Med Child Neurol. 1983;25(612).CrossRefGoogle Scholar
  4. 4.
    Lansang RS, Krouskop AC. Bladder management. In: Massagli TL, et al., editors. eMedicine. 2004.Google Scholar
  5. 5.
    Goetz LL, Klausner AP. Strategies for prevention of urinary tract infections in neurogenic bladder dysfunction. Phys Med Rehabil Clin N Am. 2014;25(3):605–18.CrossRefGoogle Scholar
  6. 6.
    McKibben MJ, Seed P, Ross SS, Borawski KM. Urinary tract infection and neurogenic bladder. Urol Clin North Am. 2015;42(4):527–36. 6.CrossRefGoogle Scholar
  7. 7.
    Bergamin PA, Kiosoglous AJ. Surgical management of recurrent urinary tract infections: a review. Transl Androl Urol. 2017;6(Suppl 2):S153–62.CrossRefGoogle Scholar
  8. 8.
    Kim BR, Lim JH, Lee SA, Kim JH, Koh SE, Lee IS, et al. The relation between postvoid residual and occurrence of urinary tract infection after stroke in rehabilitation unit. Ann Rehabil Med. 2012;36(2):248–53.CrossRefGoogle Scholar
  9. 9.
    Krebs J, Wöllner J, Pannek J. Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(9):682–6.CrossRefGoogle Scholar
  10. 10.
    Omar M, Abdul wahab-Ahmed A, Chaparala H, Monga M. Does stone removal help patients with recurrent urinary tract infections? J Urol. 2015;194(4):997–1001.CrossRefGoogle Scholar
  11. 11.
    Castle AC, Park A, Mitchell AJ, et al. Neurogenic bladder: recurrent urinary tract infections—beyond antibiotics. Curr Bladder Dysfunct Rep. 2018;13:191.CrossRefGoogle Scholar
  12. 12.
    Massa LM, Hoffman JM, Cardenas DD. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med. 2009;32(5):568–73.CrossRefGoogle Scholar
  13. 13.
    Tuel SM, Meythaler JM, Cross LL, McLaughlin S. Cost-effective screening by nursing staff for urinary tract infection in the spinal cord injured patient. Am J Phys Med Rehabil. 1990;69(3):128–31.CrossRefGoogle Scholar
  14. 14.
    National Institute on Disability and Rehabilitation Research Statement. The prevention and management of urinary tract infections amongst people with spinal cord injuries. J Am Paraplegia Soc. 1992;15:194–204.CrossRefGoogle Scholar
  15. 15.
    Hoffman JM, Wadhwani R, Kelly E, Dixit B, Cardenas DD. Nitrite and leukocyte dipstick testing for urinary tract infection in individuals with spinal cord injury. J Spinal Cord Med. 2004;27(2):128–32.CrossRefGoogle Scholar
  16. 16.
    Frimodt-Møller N, Espersen F. Evaluation of calibrated 1 and 10 microl loops and dipslide as compared to pipettes for detection of low count bacteriuria in vitro. APMIS. 2000;108(78):525–30.CrossRefGoogle Scholar
  17. 17.
    Hess MJ, Zhan EH, Foo DK, Yalla SV. Bladder cancer in patients with spinal cord injury. J Spinal Cord Med. 2003;26(4):335–8.CrossRefGoogle Scholar
  18. 18.
    Soergel TM, Cain MP, Misseri R, Gardner TA, Koch MO, Rink RC. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172:1649–51.CrossRefGoogle Scholar
  19. 19.
    Everaert K, Lumen N, Kerckhaert W, Willaert P, van Driel M. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009;64(4):335–40.CrossRefGoogle Scholar
  20. 20.
    Pannek J, Pannek-Rademacher S, Cachin-Jus M. Organ-preserving treatment of an epididymal abscess in a patient with spinal cord injury. Spinal Cord. 2014;52(Suppl 1):S7–8.CrossRefGoogle Scholar
  21. 21.
    Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33.CrossRefGoogle Scholar
  22. 22.
    Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Guidelinefor preventionofcatheter-associatedurinarytractinfections. Infect Control Hosp Epidemiol. 2010;31(4):319–26. Retrieved from. Scholar
  23. 23.
    Prieto JA, Murphy C, Moore KN, Fader MJ. Intermittent catheterisation for long-term bladder management (abridge Cochrane Review). Neurourol Urodyn. 2015;34(7):648–53.CrossRefGoogle Scholar
  24. 24.
    Cooper FP, Alexander CE, Sinha S, et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev. 2016;(7):CD011115.Google Scholar
  25. 25.
    National Clinical Guideline Centre (NICE). Infection: prevention and control of healthcare-associated infections in primary and community care: partial update of NICE clinical guideline 2 (UK). 2012;10(139).
  26. 26.
    Cicione A, Cantiello F, Ucciero G, Salonia A, Torella M, de Sio M, et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can Urol Assoc J. 2014;8(9–10):E721–7. Scholar
  27. 27.
    Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625–63.CrossRefGoogle Scholar
  28. 28.
    Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311(8):844–54.CrossRefGoogle Scholar
  29. 29.
    Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010;10:94.CrossRefGoogle Scholar
  30. 30.
    Hess MJ, Hess PE, Sullivan MR, et al. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord. 2008;46:622–6.CrossRefGoogle Scholar
  31. 31.
    Asma B, Vicky L, Stephanie D, Yves D, Amy H, Sylvie D. Standardised high dose versus low dose cranberry proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018;18(1):29.CrossRefGoogle Scholar
  32. 32.
    Toh S, Bonne Lee B, Ryan S, et al. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial. Spinal Cord. 2019;57:550–61. Scholar
  33. 33.
    Castelló T, Girona L, Gómez MR, Mena Mur A, García L. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord. 1996;34(10):592–3.CrossRefGoogle Scholar
  34. 34.
    Hetey SK, Kleinberg ML, Parker WD, Johnson EW. Effect of ascorbic acid on urine pH in patients with injured spinal cords. Am J Hosp Pharm. 1980;37(2):235–7.PubMedGoogle Scholar
  35. 35.
    Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;(10):CD003265.Google Scholar
  36. 36.
    Altarac S, Papeš D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014;113(1):9–10.CrossRefGoogle Scholar
  37. 37.
    Phé V, Pakzad M, Haslam C, et al. Open label feasibility study evaluating d-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourology and Urodynamics. 2017;36:1770–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Salisbury District HospitalWiltshireUK
  2. 2.Royal Berkshire HospitalReading, GBUK

Personalised recommendations